Use of duplicating type recombinant adenovirus

A recombinant adenovirus, replication-deficient technology, applied in the field of biomedicine, can solve problems such as weakening the therapeutic effect, and achieve the effect of wide clinical application value

Inactive Publication Date: 2008-05-28
THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] As the molecular basis of the body's resistance to various injuries, the DNA damage repair system plays a vital role in maintaining the stability and integrity of the genome. However, for radiotherapy and chemotherapy that kill cancer cells by damaging DNA, this process undoubtedly weakens the therapeutic effect. Effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of duplicating type recombinant adenovirus
  • Use of duplicating type recombinant adenovirus
  • Use of duplicating type recombinant adenovirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Construction and Identification of APE1 siRNA Adenovirus Shuttle Plasmid

[0042] according to us [4] The designed effective human APE1 siRNA sequence was analyzed and designed with the Ambion siRNA target sequence analysis system to scan the human APE1 gene cDNA coding sequence with the gene number NM_001641. 867-885 in the APE1 gene cDNA coding sequence has a specific siRNA target sequence of 19 nt in total, and the expression sequence of the human APE1 gene siRNA is designed, and the expression sequence contains the sense strand sequence, antisense strand sequence, connection The 9-base Loop loop sequence and terminal terminator sequence of the sense strand and the antisense strand, the sequence is as sequence 1 in the sequence list, and BamH I and Hind III enzyme cutting sites are introduced at both ends of the series 1, respectively. Synthesize two complementary single strands as follows:

[0043] Top strand:

[0044] 5′-GATCCGCTGGTACGACTGGAGTACCTTTCAA...

Embodiment 2

[0048] Example 2 Ad5 / F35-APE1siRNA recombinant adenovirus packaging, amplification and purification 2.1 Ad5 / F35-APE1siRNA recombinant adenovirus packaging

[0049] Packaging principle and flow chart: The recombinant adenovirus is constructed using the adenovirus Ad5 / F35MaxTM packaging system of Benyuan Zhengyang Company. The shuttle plasmid pDC316-EGFP-U6-APE1siRNA carrying the human APE1 gene siRNA expression sequence and the adenovirus backbone plasmid pBHG-fiber5 / 35 were co-transfected into 293 cells. Plasmids are combined, and Cre / loxP system is used to perform site-directed recombination in 293 cells to produce Ad5 / F35-APE1 siRNA recombinant adenovirus with human APE1 gene siRNA expression sequence. The recombinant virus obtained in this way is a replication-deficient adenovirus with E1 deletion, and the virus can only realize the expression of foreign genes in cells that cannot provide the E1 region, but does not have the ability to proliferate. The packaging process of...

Embodiment 3

[0073] Example 3 Infection Efficiency of Ad5 / F35-APElsiRNA Recombinant Adenovirus to Colorectal Cancer Cells

[0074] 3.1 Detection of Infection Efficiency in Vitro

[0075] LOVO cells were cultured in an incubator containing 5% CO2 at 37°C, and the culture medium RPMI1640 contained 10% FCS, 1.0×10 5 U / L penicillin and streptomycin. The day before adenovirus infection, LOVO cells were seeded in a six-well plate, 5×10 per well 5 cells. Infect LOVO cells with adenovirus Ad5 / F35-APE1siRNA or control adenovirus Ad5 / F35-EGFP and Ad5-EGFP at a multiplicity of infection (MOI) of 0-20 for 90 min, then discard the culture medium and replace with complete medium After 24h, the expression of EGFP in LOVO cells was observed under a fluorescent inverted microscope and photographed. Digest the cells with 0.25% trypsin, centrifuge at 500g for 5min at room temperature, discard the supernatant, resuspend the cells in 0.01M PBS, centrifuge at 500g for 5min at room temperature, collect the c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a usage of a replication-defective recombinant adenovirus which contains the expression sequence of human APE1 gene siRNA, and the invention can be used in the preparation of the drugs to play sensitizing effect in the radiotherapy and/or chemotherapy of malignant tumors. The expression sequence of human APE1 gene siRNA is inserted below the U6 promoter of adenovirus shuttle plasmid, so as to construct shuttle plasmid pDC316-EGFP-U6-APE1siRNA, and the latter and adenovirus backbone plasmid pBHG-fiber5/35 transfect 293 cells in total, and the Ad5/F35-APE1siRNA recombinant adenovirus containing the expression sequence of human APE1 gene siRNA is obtained by fixed-point recombinant by a Cre/loxP system. The recombinant adenovirus can be made into the injection liquid with certain titer, be used in the combined application in the radiotherapy and/or chemotherapy of malignant tumors, effectively control the expression of APE1 gene and effectively enhance the sensitivity to the radiotherapy and/or chemotherapy of malignant tumors.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular to the use of a replication-deficient recombinant adenovirus for preparing a drug for treating malignant tumors. The recombinant adenovirus uses Ad5 / F35 adenovirus as a therapeutic carrier and uses RNAi technology to effectively inhibit the expression of APE1 gene . Background technique [0002] As the molecular basis of the body's resistance to various injuries, the DNA damage repair system plays a vital role in maintaining the stability and integrity of the genome. However, for radiotherapy and chemotherapy that kill cancer cells by damaging DNA, this process undoubtedly weakens the therapeutic effect. Effect. Therefore, gene therapy targeting DNA damage repair genes is expected to effectively enhance the sensitivity of tumor cells to radiotherapy and cytotoxic chemotherapy drugs. [0003] APE1 is a model of the most structural and functional characteristics of biological macr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61P35/00C12N15/861
Inventor 向德兵王东陈正堂谢家印李梦侠仲召阳
Owner THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap